Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
RTNominal down15.660 -0.220 (-1.385%)

15/10/2021 15:52

Hansoh Pharma (03692) signs licensing agreement

[ET Net News Agency, 15 October 2021] Hansoh Pharmaceutical Group Company Limited
(03692) said the company has entered into an exclusive licence and collaboration agreement
with Silence Therapeutics plc (Silence Therapeutics).
The company and Silence Therapeutics will collaborate to develop siRNAs (short
interfering RNAs) for three targets leveraging Silence Therapeutics' proprietary mRNAi GOL
platform. For the first two targets, the company will have the exclusive option to licence
rights in China (including Hong Kong, Macau and Taiwan) (the territory) following the
completion of phase 1 studies and Silence Therapeutics will retain exclusive rights in
rest of the world other than the territory. Silence Therapeutics will be responsible for
all activities up to option exercise and will retain responsibility for development
outside the territory post phase 1 studies for the first two targets. For the third
target, the company will have the exclusive option to licence global rights at the point
of Investigational New Drug (IND) filing. The company will be responsible for all
development activities post option exercise for the third target. (RC)

Remark: Real time quote last updated: 28/01/2022 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2022 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.